Closed Blood Sampling System Market Analysis & Forecast: 2026-2033
The Closed Blood Sampling System Market size is anticipated to grow at a CAGR of 6.9% with USD 1,030 Mn in 2026 and is expected to reach USD 1,650 Mn in 2033. The primary drivers are defined by rising intensive-care admissions, frequent arterial blood testing, stronger infection-control practices, and efforts to reduce iatrogenic blood loss and occupational exposure. CDC estimates that hospital-based healthcare personnel sustain approximately 385,000 needlestick and other sharps-related injuries annually. Additionally, a systematic review in NIH’s PubMed Central found that closed blood sampling devices reduced diagnostic blood loss by 25%. These safety and blood-conservation benefits are strengthening demand for closed sampling systems and accessories across intensive care units, emergency departments, operating rooms, hospitals, and nursing homes.
On the basis of product type, the blood sampling system segment is projected to account for the largest Closed Blood Sampling System Market share of 63.4% in 2026. The segment’s growth is owing to the hospitals’ need for repeated samples while limiting blood exposure, contamination, discarded clearing volume, and venipunctures.
CDC’s laboratory review found hospital blood-culture contamination rates ranging from 0.6% to 12.5%, despite an accepted maximum of 3%, supporting systems that standardize collection and reduce handling-related contamination. Closed sampling reservoirs can return clearing blood to patients, making them valuable in intensive care, operating rooms, neonatal care, and arterial monitoring.
To learn more about this report, Request Free Sample
On the basis of application, the diagnostic segment lead with a major 68.7% share in 2026. The growth is owing to the central role of blood testing in clinical decision-making and infection diagnosis.
CDC reports that around 14 billion laboratory tests are performed annually in the U.S., sustaining demand for reliable, low-contamination specimen collection. CDC also states that 70% of medical decisions depend on laboratory test results, emphasizing the importance of sample integrity, repeatable access, and fewer pre-analytical errors.
In December 2025, BD Indonesia launched the BD Nexiva Closed IV Catheter System, expanding access to integrated closed vascular-access technology. Its compatibility with PIVO Pro needle-free blood-draw technology supports blood collection through existing IV access and strengthens diagnostic workflow adoption.
The U.S. market is shifting from conventional venipuncture-based blood collection toward technologies that permit blood to be drawn from an existing peripheral intravenous catheter. This model is designed to reduce repeated needle insertions, improve the patient experience, simplify nursing workflows, and support hospital efforts to create a “one-stick” care pathway. Needle-free peripheral-line systems typically introduce a flexible internal flow tube through the existing catheter so that blood can be collected beyond the catheter tip, where flow conditions are more suitable for obtaining a reliable specimen.
In January 2025, Becton, Dickinson and Company and Carilion Clinic announced the implementation of the BD PIVO Pro Needle-free Blood Collection Device across Carilion’s inpatient care environment. Carilion became the first health system in Virginia and the southeastern U.S. to offer the technology for inpatient needle-free blood draws. The system uses an existing peripheral IV catheter and is intended to reduce additional needlesticks, discomfort, and anxiety while supporting the collection of reliable blood specimens. Carilion serves more than one million people, providing a substantial implementation environment for evaluating workflow and patient-care benefits.
Closed-loop blood conservation systems are designed to maintain a sealed connection between the patient’s vascular catheter, pressure-monitoring line, sampling reservoir, and collection port. During arterial or central-line sampling, the system draws the saline-diluted clearing volume into an in-line reservoir. Once the diagnostic specimen is collected, the clearing volume can be returned to the patient. This reduces blood waste, limits unnecessary line disconnections, and lowers opportunities for environmental exposure or intraluminal contamination.
Clinical evidence demonstrates a meaningful reduction in diagnostic blood loss. In the ENCLOSE randomized pilot trial, patients using a closed-loop collection system recorded mean daily blood loss of 15.5 mL, compared with 32.7 mL for patients using open sampling. Another blood-saving bundle combining a closed arterial-line system, small-volume tubes, and reduced sampling frequency lowered mean daily diagnostic blood loss from 43.3 mL to 15.0 mL. The study also recorded red-cell transfusion in 8.0% of intervention patients, compared with 31.7% in the control group, although its longitudinal design requires cautious interpretation.
|
Current Event |
Description and its Impact |
|
FDA Quality Management System Regulation Implementation in the U.S.
|
|
|
Mandatory EUDAMED Modules Across the European Union |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
The North America region accounts for 38.6% of the market share in 2026. The region’s growth is owing to the hospital safety programs, advanced laboratory infrastructure, and demand for needle-free blood collection.
CDC reported that the BD continuous-monitoring blood culture platform is used in about half of U.S. laboratories, indicating a large installed base for standardized blood-culture collection workflows.
In February 2025, the U.S. FDA cleared BD’s PIVO Pro needle-free blood collection device for collecting venous specimens into vacuum tubes, syringes, and blood-culture bottles from peripheral IV catheters. The clearance added blood-culture collection at initial catheter placement and extended shelf life to three years.
Asia Pacificis expected to witness strong growth in market over the forecast period. The region’s growth is owing to the expanding hospital activity, intensive-care demand, and initiatives to reduce repeated venipuncture.
Australia recorded 12.8 million hospitalizations in 2024–25, including 7.7 million in public hospitals, indicating substantial demand for routine inpatient blood collection. The Australian Institute of Health and Welfare also reported 156,000 hospitalizations involving level 3 intensive-care units during 2024–25, where frequent sampling and blood-conservation practices are particularly relevant.
In a February 2026 development, the Australian New Zealand Clinical Trials Registry listed the PIVO Trial as recruiting, with a target enrolment of 1,148 adults across four Queensland hospitals. The randomized study is evaluating whether the PIVO Pro needle-free collection device, used through newly inserted peripheral intravenous catheters, can reduce blood-culture contamination and underfilled bottles versus standard collection.
In the United States, the Closed Blood Sampling System Market is influenced by the efforts to improve blood-culture accuracy and reduce preanalytical contamination. CDC analyzed more than 5.2 million blood-culture episodes and identified unequal contamination risks across patient and facility groups, highlighting the need for standardized, protected collection workflows.
In March 31, 2026, CDC released its updated Prevent Adult Blood Culture Contamination Quality Tool, incorporating contamination and single-set monitoring methods for laboratories. This development encourages hospitals to adopt closed, needleless blood-draw technologies that limit environmental exposure, support specimen collection, and improve diagnostic reliability across emergency departments, intensive-care units, and inpatient laboratories.
China is emerging as a major growth market for Closed Blood Sampling System. The growth is owing to the expanding hospital workloads and demand for safer, standardized specimen collection. China’s National Health Commission reported 2.67 billion hospital visits during January–July 2025, including 2.24 billion visits to public hospitals, creating substantial recurring demand for blood-draw and laboratory consumables.
In April 2025, the National Medical Products Administration recorded approval of Smiths Medical’s arterial blood sampler kit, with approval dated April 3. This regulatory development broadens access to dedicated arterial sampling technology and supports adoption in intensive-care, respiratory, emergency, and perioperative settings requiring frequent, contamination-controlled blood-gas collection.
Some of the major key players in Closed Blood Sampling System Market are Edwards Lifesciences Crop, ICU Medical, Inc., Smiths Medical, CardioMed Supplies Inc., Argon Medical Devices, Inc., Utah Medical Products, Inc., fannin Ltd., Velano Vascular, Inc., Ashcon International Inc., and Merit Medical Systems, Inc.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,030 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.9% | 2033 Value Projection: | USD 1,650 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Edwards Lifesciences Crop, ICU Medical, Inc., Smiths Medical, CardioMed Supplies Inc., Argon Medical Devices, Inc., Utah Medical Products, Inc., fannin Ltd., Velano Vascular, Inc., Ashcon International Inc., and Merit Medical Systems, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
